Fig. 4: Long-term in vivo performance of VEPs.
From: Directed self-assembly of a xenogeneic vascularized endocrine pancreas for type 1 diabetes
A Schematic representation of in vivo experimental protocol. Created with Biorender. B Weekly not fasting glycemia profile comparison between DL-NPIs (red, n = 8 implantations), LV-NPIs (yellow, n = 4 implantations), VEPs (blue, n = 20 implantations) and KC-NPIs (black, n = 10 implantations) for 9, 14, or 18 weeks follow up (# represents graft explants: 9 weeks VEP n = 4 explants; 14 weeks KC-NPIs=1explants; VEPs n = 4 explants; 18 weeks KC-NPIs n = 3 explants, VEPs n = 2 explants). Values presented as Mean ± SEM. (**** VEPs vs. DL-NPIs p = 4.98e-39; VEPs vs. KC-NPIs p = 3.85e-29, and VEPs vs. LV-NPIs p = 2.01e-25; general linear model for repeated measures corrected by Bonferroni). C Kaplan Mayer analysis of the percentage of mice reaching normoglycaemia (≤200 mg/dl). Differences between VEPs, DL-NPIs, KC-NPIs and LV-NPIs were estimated by Log Rank test adjusted for multiple comparisons with Benjamini & Hochberg method. (**** VEPs vs. DL-NPIs p = 1.2e-05; VEPs vs. KC-NPIs p = 1.2e-05; *** VEPs vs. LV-NPIs p = 0.00074). D VEPs (n = 5 mice), DL-NPIs (n = 3 mice), KC-NPIs (n = 3 mice) and LV-NPIs (n = 3 mice) OGTT performance 9 weeks after transplantation. Values presented as mean ± SEM. E OGTT AUC over 120 min at 9 weeks after implantation (n = 5 in VEPs mice, n = 3 in DL-NPIs mice, n = 3 in KC-NPIs mice and n = 3 LV-NPIs mice). * p = 0.0463; one way Anova for multiple comparison corrected for Dunn’s. Values presented as mean ± SD. Source data are provided as a Source Data file.
